ArticleGynecologic oncology2017
Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Article in Gynecologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neoadjuvant Chemotherapy in Advanced Stage Endometrial Cancer: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis.American journal of obstetrics and gynecology · 2021Pooled it
- A nomogram for predicting prognosis in uterine serous carcinoma: a large population-based cohort study with external validation.Frontiers in oncology · 2026Article
- Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer.Cancer medicine · 2026Article
- A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer.Molecular biology reports · 2023Review
- Endometrial serous carcinoma: A retrospective review of histological features & their clinicopathological association with disease-free survival & overall survival.The Indian journal of medical research · 2022Article
- Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.Oncotarget · 2022Article
- Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.BMC cancer · 2021Article
- Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review.Gynecologic oncology reports · 2021Article
- Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma.Gynecologic oncology reports · 2021Article
- Impact of positive cytology in uterine serous carcinoma: A reassessment.Gynecologic oncology reports · 2021Article
- A 4-gene signature predicts prognosis of uterine serous carcinoma.BMC cancer · 2021Article
- Stage III uterine serous carcinoma: modern trends in multimodality treatment.Journal of gynecologic oncology · 2020Article
- Dendritic cell engineering for selective targeting of female reproductive tract cancers.The Indian journal of medical research · 2018Review
- Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.Annals of surgical oncology · 2018Article
- MicroRNA-200c Inhibits Epithelial-Mesenchymal Transition by Targeting the BMI-1 Gene Through the Phospho-AKT Pathway in Endometrial Carcinoma Cells In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesThe study objective was to analyze the impact of prognostic factors, including treatment modality, on outcome in patients with advanced-stage uterine serous carcinoma (USC).
methodsA retrospective review of patients diagnosed with stage III or IV USC between 1993 and 2012 was performed. Summary statistics were used to describe demographic and clinical characteristics. Overall survival (OS) and recurrence free survival (RFS) were estimated by Kaplan-Meier analysis. Cox proportional hazards regression was used to model the association of potential prognostic factors with OS and RFS.
resultsThe study included 260 patients with median follow-up of 26.6months (range 1-172.8). Median age was 63years (range 30-88) and 52.3% had stage III disease. In all, 60% were treated with surgery followed by chemotherapy, 18.1% received surgery, chemotherapy, and radiotherapy, 11.5% had surgery and radiotherapy, and 10.4% had neoadjuvant chemotherapy. The overall complete response rate was 68.9%, and the cumulative incidence of recurrence was 82.7%. Treatment that included surgery, chemotherapy, and radiation and stage III disease were associated with improved RFS on multivariate analysis. For OS, therapy with surgery, chemotherapy, and radiation, mixed histology, and stage III disease were associated with better OS on multivariate analysis.
conclusionsPatients with advanced-stage USC have a poor prognosis, regardless of clinical factors or treatment received. However, combination therapy that includes chemotherapy and radiation appears to be associated with improved survival in these women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.